Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year.If left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five years.The cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA levels.Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC.The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis.Here,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.
展开▼